Safety and Efficacy of Gene Transfer for Leber's Congenital Amaurosis
Open accessThe DOI matches its Crossref record; 26 of the 27 references it cites were found in a registry or an index.
Abstract
Leber's congenital amaurosis (LCA) is a group of inherited blinding diseases with onset during childhood. One form of the disease, LCA2, is caused by mutations in the retinal pigment epithelium-specific 65-kDa protein gene (RPE65). We investigated the safety of subretinal delivery of a recombinant adeno-associated virus (AAV) carrying RPE65 complementary DNA (cDNA) (ClinicalTrials.gov number, NCT00516477 [ClinicalTrials.gov]). Three patients with LCA2 had an acceptable local and systemic adverse-event profile after delivery of AAV2.hRPE65v2. Each patient had a modest improvement in measures of retinal function on subjective tests of visual acuity. In one patient, an asymptomatic macular hole developed, and although the occurrence was considered to be an adverse event, the patient had some return of retinal function. Although the follow-up was very short and normal vision was not achieved, this study provides the basis for further gene therapy studies in patients with LCA.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The main disadvantage of this approach is the surgery itself. Traditional vitrectomy complications such as cataract, IOP rise and retinal tears, as well as subretinal injection-related complications such as a macular hole.4,87,88”
From Ocular Gene Therapy: A Literature Review with Special Focus on Immune and Inflammatory Responses (2022) · cites this paper as [88]
In the citing paper
“Many current retinal gene therapy trials adopt a standardized immunosuppression protocol up to 21 days post-treatment, which may ameliorate this immune response in humans.6,7,40”
From Characterizing the cellular immune response to subretinal AAV gene therapy in the murine retina (2021) · cites this paper as [40]
In the citing paper
“Despite a 28-day oral corticosteroid therapy started 2 days before the first IVT, a regimen similar to that provided in several other clinical studies using IVT or sub-retinal AAV-based gene therapies,41–45 70.7% of lenadogene nolparvovec-treated eyes developed some degree of intraocular inflammation versus 10.2% of placebo-treated eyes.”
From Randomized trial of bilateral gene therapy injection for m.11778G>A MT-ND4 Leber optic neuropathy (2023) · cites this paper as [42]
In the citing paper
“during Phase I/II clinical trials for Leber's congenital amaurosis (LCA), over 30 patients who received a subretinal injection of AAV2 encoding RPE65, an enzyme responsible for the isomerohydrolase activity of retinal pigment epithelium, showed sustained improvement in both subjective and objective measurements of vision.8–14”
From Antibody neutralization poses a barrier to intravitreal adeno-associated viral vector gene delivery to non-human primates (2015) · cites this paper as [11]
In the citing paper
“As a result, AAV clinical successes to date have involved delivery either to immune privileged regions or to subjects lacking apparent AAV immunological memory.8–14,30,42”
From Antibody neutralization poses a barrier to intravitreal adeno-associated viral vector gene delivery to non-human primates (2015) · cites this paper as [11]
9 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Gene therapy restores vision in a canine model of childhood blindness
Acland, G. M., Aguirre, G. D., Ray, J., Zhang, Q., Aleman, T. S., Cideciyan, A. V., Pearce-Kelling, S. E., Anand, V., Zeng, Y., Maguire, A. M., et al. (2001) · Nature Genetics · doi:10.1038/ng0501-92 · Cited by 1,202
Self-citationIdiopathic Senile Macular Hole: Its Early Stages and Pathogenesis
Gass, J. D. M. (1988) · Archives of Ophthalmology · doi:10.1001/archopht.1988.01060130683026 · Cited by 992
Rpe65 is necessary for production of 11-cis-vitamin A in the retinal visual cycle
Redmond., T. M., Yu, S., Lee, E., Bok, D., Hamasaki, D., Chen, N., Goletz, P., Ma, J.-X., Crouch, R. K., & Pfeifer, K. (1998) · Nature Genetics · doi:10.1038/3813 · Cited by 929
Self-citationMutations in RPE65 cause autosomal recessive childhood–onset severe retinal dystrophy
Gu, S.-M., Thompson, D. A., Srikumari, C. R. S., Lorenz, B., Finckh, U., Nicoletti, A., Murthy, K. R., Rathmann, M., Kumaramanickavel, G., Denton, M. J., et al. (1997) · Nature Genetics · doi:10.1038/ng1097-194 · Cited by 663
RPE65 is the isomerohydrolase in the retinoid visual cycle
Moiseyev, G., Chen, Y., Takahashi, Y., Wu, B. X., & Ma, J.-X. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0503460102 · Cited by 536
Self-citationAcland, G. M., Aguirre, G. D., Bennett, J., Aleman, T. S., Cideciyan, A. V., Bennicelli, J., Dejneka, N. S., Pearce-Kelling, S. E., Maguire, A. M., Palczewski, K., et al. (2005) · Molecular Therapy · doi:10.1016/j.ymthe.2005.08.008 · Cited by 477
Self-citationRpe65 is the retinoid isomerase in bovine retinal pigment epithelium
Jin, M., Li, S., Moghrabi, W. N., Sun, H., & Travis, G. H. (2005) · Cell · doi:10.1016/j.cell.2005.06.042 · Cited by 424
Redmond, T. M., Poliakov, E., Yu, S., Tsai, J.-Y., Lu, Z., & Gentleman, S. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0504167102 · Cited by 409
Self-citationNatural Course of Retinitis Pigmentosa Over a Three-Year Interval
Berson, E. L., Sandberg, M. A., Rosner, B., Birch, D. G., & Hanson, A. H. (1985) · American Journal of Ophthalmology · doi:10.1016/0002-9394(85)90351-4 · Cited by 321
Jacobson, S. G., Aleman, T. S., Cideciyan, A. V., Sumaroka, A., Schwartz, S. B., Windsor, E. A. M., Traboulsi, E. I., Heon, E., Pittler, S. J., Milam, A. H., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0500646102 · Cited by 274
Self-citation
Research works printed but not linked: 4
- Lorenz B, 2000, Invest Ophthalmol Vis Sci, 41, 2735
- Aguirre GD, 1998, Mol Vis, 4, 23
- 10.1038/88327 · DOI
- Fosnaugh JS, 1992, Methods Find Exp Clin Pharmacol, 14, 545
Cited by
Items 701–800 of 1,031
Nanoparticle-mediated gene transfer specific to retinal pigment epithelial cells
Koirala, A., Makkia, R. S., Cooper, M. J., & Naash, M. I. (2011) · Biomaterials · doi:10.1016/j.biomaterials.2011.08.062 · Cited by 47
“gov) using recombinant adeno-associated viral (rAAV) vectors [19–23].”
The gene therapy journey for hemophilia: are we there yet?
High, K. A. (2012) · PubMed · doi:10.1182/asheducation-2012.1.375 · Cited by 48
Self-citationSamardzija, M., Tanimoto, N., Kostic, C., Beck, S., Oberhauser, V., Joly, S., Thiersch, M., Fahl, E., Arsenijevic, Y., von Lintig, J., et al. (2009) · Human Molecular Genetics · doi:10.1093/hmg/ddp026 · Cited by 48
Historic Overview of Genetic Engineering Technologies for Human Gene Therapy
Tamura, R., & Toda, M. (2020) · Neurologia medico-chirurgica · doi:10.2176/nmc.ra.2020-0049 · Cited by 62
Koirala, A., Conley, S. M., Makkia, R., Liu, Z., Cooper, M. J., Sparrow, J. R., & Naash, M. I. (2013) · Journal of Controlled Release · doi:10.1016/j.jconrel.2013.08.299 · Cited by 47
“S/MAR-containing DNA nanoparticles promote persistent RPE gene expression and improvement in RPE65-associated LCA.”
BackgroundInfluentialCruz, N. M., Yuan, Y., Leehy, B. D., Baid, R., Kompella, U., DeAngelis, M. M., Escher, P., & Haider, N. B. (2014) · PLoS ONE · doi:10.1371/journal.pone.0087942 · Cited by 47
Prediction of adeno-associated virus neutralizing antibody activity for clinical application
Wang, M., Crosby, A., Hastie, E., Samulski, J. J., McPhee, S., Joshua, G., Samulski, R. J., & Li, C. (2015) · Gene Therapy · doi:10.1038/gt.2015.69 · Cited by 45
Hippert, C., Ibanes, S., Serratrice, N., Court, F., Malecaze, F., Kremer, E. J., & Kalatzis, V. (2012) · PLoS ONE · doi:10.1371/journal.pone.0035318 · Cited by 46
“The retina has received the most attention in recent years culminating in the successful clinical trials in 2008 for Leber’s congenital amaurosis, a hereditary congenital blindness due to a breakdown of the visual cycle [16,17].”
Bogner, B., Boye, S. L., Min, S.-H., Peterson, J. J., Ruan, Q., Zhang, Z., Reitsamer, H. A., Hauswirth, W. W., & Boye, S. L. (2015) · PLoS ONE · doi:10.1371/journal.pone.0128759 · Cited by 48
Optogenetic Modulation of Urinary Bladder Contraction for Lower Urinary Tract Dysfunction
Park, J. H., Hong, J. K., Jang, J. Y., An, J., Lee, K., Kang, T. M., Shin, H. J., & Suh, J. F. (2017) · Scientific Reports · doi:10.1038/srep40872 · Cited by 54
Evaluation of Approaches to Analyzing Continuous Correlated Eye Data When Sample Size Is Small
Huang, J. Y., Huang, J., Chen, Y., & Ying, G. (2017) · Ophthalmic Epidemiology · doi:10.1080/09286586.2017.1339809 · Cited by 51
“retinal gene therapy of eye disease.(2,3) The treatment effect is quantified by the mean difference of the continuous outcome measure between the treated eye and the untreated fellow eye.”
BackgroundCabanes‐Creus, M., Westhaus, A., Navarro, R. G., Baltazar, G., Zhu, E., Amaya, A. K., Liao, S. H. Y., Scott, S., Sallard, E., Dilworth, K. L., et al. (2020) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2020.05.004 · Cited by 45
Iron metabolism in the eye: A review
Goralska, M., Ferrell, J., Harned, J., Lall, M. M., Nagar, S., Fleisher, L. N., & McGahan, M. C. (2008) · Experimental Eye Research · doi:10.1016/j.exer.2008.10.026 · Cited by 56
“This knowledge has formed the basis for gene therapy which has shown success in human patients with Leber’s amaurosis (Bainbridge et al. 2008; Cideciyan et al. 2008; Maguire et al. 2008).”
BackgroundGruntman, A. M., Su, L., Su, Q., Gao, G., Mueller, C., & Flotte, T. R. (2015) · Human Gene Therapy Methods · doi:10.1089/hgtb.2015.040 · Cited by 46
Evaluation of AAV-DJ vector for retinal gene therapy
Katada, Y., Kobayashi, K., Tsubota, K., & Kurihara, T. (2019) · PeerJ · doi:10.7717/peerj.6317 · Cited by 46
Clinical and Rehabilitative Management of Retinitis Pigmentosa:Up-to-Date
Nadai, K. D., Romano, M., Binotto, A., Costagliola, C., Sato, G., & Parmeggiani, F. (2011) · Current Genomics · doi:10.2174/138920211795860125 · Cited by 62
“The emotional impact to researchers, clinicians, patients, and families from the recent results in molecular diagnosis, gene therapy and other pioneering treatments is very evident [6, 105-130].”
BackgroundManfredsson, F., Okun, M., & Mandel, R. (2009) · Current Gene Therapy · doi:10.2174/156652309789753400 · Cited by 50
“In contrast, in a relatively immunoprivileged site such as the retina, early clinical trials have revealed little or no immune response as well as some clinical effect [113-115].”
BackgroundKu, C. A., Chiodo, V. A., Boye, S. L., Goldberg, A. F. X., Li, T., Hauswirth, W. W., & Ramamurthy, V. (2011) · Human Molecular Genetics · doi:10.1093/hmg/ddr391 · Cited by 46
Gene Therapy of Inherited Retinal Degenerations: Prospects and Challenges
Trapani, I., Banfi, S., Simonelli, F., Surace, E. M., & Auricchio, A. (2015) · Human Gene Therapy · doi:10.1089/hum.2015.030 · Cited by 47
“However, subretinal injections are technically challenging, and concerns about their invasiveness, especially in patients with diseased retinas, have been raised in some of the LCA2 clinical trials in which foveal thinning, macular holes, choroidal effusions, and ocular hypo- and hypertension have been reported.(11,18…”
BackgroundSelf-citationTreweek, J. B., & Gradinaru, V. (2016) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2016.03.012 · Cited by 46
Tzameret, A., Ketter-Katz, H., Edelshtain, V., Sher, I., Corem‐Salkmon, E., Levy, I., Last, D., Guez, D., Mardor, Y., Margel, S., et al. (2019) · Journal of Nanobiotechnology · doi:10.1186/s12951-018-0438-y · Cited by 49
Li, H., Lin, S.-W., Giles-Davis, W., Li, Y., Zhou, D., Xiang, Z. Q., High, K. A., & Ertl, H. C. (2009) · Molecular Therapy · doi:10.1038/mt.2009.79 · Cited by 46
Self-citationThe use of canine models of inherited retinal degeneration to test novel therapeutic approaches
Beltran, W. A. (2009) · Veterinary Ophthalmology · doi:10.1111/j.1463-5224.2009.00694.x · Cited by 55
Mutational Screening of LCA Genes Emphasizing RPE65 in South Indian Cohort of Patients
Verma, A., Vijayalakshmi, P., Shetty, S. B., Külm, M., & Sundaresan, P. (2013) · PLoS ONE · doi:10.1371/journal.pone.0073172 · Cited by 47
“For the management of LCA patients, the most promising aspect is the gene therapy success for RPE65 LCA cases, achieved in phase 2&1 clinical trials and previous animal model studies, which have paved the pathway to cure inherited blindness [11,12].”
BackgroundLi, W., Kong, F., Li, X., Dai, X., Liu, X., Zheng, Q., Wu, R., Zhou, X., Lü, F., Chang, B., et al. (2009) · PubMed Central · Cited by 54
Improving adeno‐associated vector yield in high density insect cell cultures
Mena, J. A., Aucoin, M. G., Montes, J., Chahal, P. S., & Kamen, A. (2010) · The Journal of Gene Medicine · doi:10.1002/jgm.1420 · Cited by 45
“trials [1] for the treatment of different diseases, including Alzheimer’s disease [2], Parkinson’s disease [3], cystic fibrosis [4], hemophilia B [5], retinal diseases [6], and rheumatoid arthritis [7].”
Backgroundβ-Cell–Specific IL-2 Therapy Increases Islet Foxp3+Treg and Suppresses Type 1 Diabetes in NOD Mice
Johnson, M. C., Garland, A. L., Nicolson, S. C., Li, C., Samulski, R. J., Wang, B., & Tisch, R. (2013) · Diabetes · doi:10.2337/db13-0669 · Cited by 47
“Indeed, AAV vectors have been successfully applied in the clinic to complement various genetic disorders (32-34).”
BackgroundAskou, A. L., Alsing, S., Holmgaard, A., Bek, T., & Corydon, T. J. (2017) · Acta Ophthalmologica · doi:10.1111/aos.13407 · Cited by 49
“…has been shown to be safe and effective for untreatable rare retinal diseases such as Leber congenital amaurosis which has drawn attention to this therapy as a potential treatment for more common blinding diseases such as AMD (Bainbridge et al. 2008; Hauswirth et al. 2008; Maguire et al. 2008).”
BackgroundGene and Induced Pluripotent Stem Cell Therapy for Retinal Diseases
Maeda, A., Mandai, M., & Takahashi, M. (2019) · Annual Review of Genomics and Human Genetics · doi:10.1146/annurev-genom-083118-015043 · Cited by 55
Jacobson, S. G., Cideciyan, A. V., Ho, A. C., Peshenko, I. V., Garafalo, A. V., Román, A. J., Sumaroka, A., Wu, V. F., Krishnan, A. K., Sheplock, R., et al. (2021) · iScience · doi:10.1016/j.isci.2021.102409 · Cited by 52
AAV for pain: steps towards clinical translation
Beutler, A. S., & Reinhardt, M. (2009) · Gene Therapy · doi:10.1038/gt.2009.23 · Cited by 47
Evaluation of 9-cis-Retinyl Acetate Therapy in Rpe65−/−Mice
Maeda, T., Maeda, A., Casadesus, G., Palczewski, K., & Margaron, P. (2009) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.09-3700 · Cited by 45
“Gene therapy trials with recombinant adenoassociated virus were performed in LCA patients with RPE65 mutations.(21,22,43) The results seem encouraging, so the same approach may apply to patients with different LCA gene mutations and forms of retinal degeneration.”
ResultWang, Z., Lisowski, L., Finegold, M. J., Nakai, H., Kay, M. A., & Grompe, M. (2012) · Molecular Therapy · doi:10.1038/mt.2012.157 · Cited by 44
Dev Borman, A., Ocaka, L. A., Mackay, D. S., Ripamonti, C., Henderson, R. H., Moradi, P., Hall, G., Black, G. C., Robson, A. G., Holder, G. E., et al. (2012) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.12-9548 · Cited by 44
Hammadi, S., Tzoumas, N., Ferrara, M., Meschede, I. P., Lo, K., Harris, C., Lako, M., & Steel, D. H. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12082870 · Cited by 44
Retinal Structure in RPE65-Associated Retinal Dystrophy
Kumaran, N., Georgiou, M., Bainbridge, J. W. B., Bertelsen, M., Larsen, M., Blanco-Kelly, F., Ayuso, C., Tran, H. V., Munier, F. L., Kalitzeos, A., et al. (2020) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.61.4.47 · Cited by 44
Sodi, A., Banfi, S., Testa, F., Della Corte, M., Passerini, I., Pelo, E., Rossi, S., Simonelli, F., & Italian IRD Working Group (2021) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-021-01868-4 · Cited by 44
Self-citationRetinal Gene Therapy Coming of Age
Cepko, C. L., & Vandenberghe, L. H. (2013) · Human Gene Therapy · doi:10.1089/hum.2013.050 · Cited by 43
“In the first reports from the LCA2 trials, vision tests were primarily used to evaluate efficacy.”
InfluentialGene therapy for Leber congenital amaurosis: advances and future directions
Hufnagel, R. B., Ahmed, Z. M., Corrêa, Z. M., & Sisk, R. A. (2012) · Graefe's Archive for Clinical and Experimental Ophthalmology · doi:10.1007/s00417-012-2028-2 · Cited by 44
“Gene therapy trials in human LCA patients The first human trials to test the safety of viral vectormediated gene transfer to human LCA patients were reported in 2008 by three groups; from University College London, a collaboration between Children’s Hospital of Philadelphia (CHoP) and Italy, and a collaboration betwee…”
BackgroundInfluentialJin, S.-Y., Xiao, J., Bao, J., Zhou, S., Wright, J. F., & Zheng, X. L. (2013) · Blood · doi:10.1182/blood-2013-02-486779 · Cited by 44
“Recent clinical studies using adeno-associated virus (AAV)-based gene delivery vectors have documented safety and long-term expression of therapeutic transgenes for two human genetic diseases.(12,13) In this study, we report the safety and efficacy of AAV8mediated expression of a C-terminal truncated ADAMTS13 variant…”
BackgroundSelf-citationTesta, F., Surace, E. M., Rossi, S., Marrocco, E., Gargiulo, A., Di Iorio, V., Ziviello, C., Nesti, A., Fecarotta, S., Bacci, M. L., et al. (2011) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.10-6543 · Cited by 44
“To this end we have used a dose of AAV2/8 similar to that used in the RPE65 clinical trial conducted by Maguire et al.5 In addition, we used a vitreoretinal surgical protocol for subretinal administration of the vector similar to that used in RPE65 patients.2–6 We subretinally injected monolaterally 1 1010 (genome cop…”
MethodSelf-citationTolmachova, T., Tolmachov, O. E., Wavre‐Shapton, S. T., Tracey‐White, D., Futter, C. E., & Seabra, M. C. (2012) · The Journal of Gene Medicine · doi:10.1002/jgm.1652 · Cited by 44
Mookherjee, S., Hiriyanna, S., Kaneshiro, K., Li, L., Li, Y., Li, W., Qian, H., Li, T., Khanna, H., Colosi, P., et al. (2015) · Human Molecular Genetics · doi:10.1093/hmg/ddv354 · Cited by 43
Ashtari, M., Nikonova, E. S., Marshall, K. A., Young, G. J., Aravand, P., Pan, W., Ying, G.-S., Willett, A. E., Mahmoudian, M., Maguire, A. M., et al. (2017) · Ophthalmology · doi:10.1016/j.ophtha.2017.01.029 · Cited by 44
Self-citationConflict of interest: the authors declare no conflict of interest.
Baygildin, S. S., Мусина, Л. А., & Khismatullina, Z. R. (2021) · Journal Biomed · doi:10.33647/2074-5982-17-1-70-81 · Cited by 45
Bouaita, A., Augustin, S., Lechauve, C., Cwerman‐Thibault, H., Bénit, P., Simonutti, M., Pâques, M., Rustin, P., Sahel, J., & Corral‐Debrinski, M. (2011) · Brain · doi:10.1093/brain/awr290 · Cited by 46
“…al., 2010) and since clinical trials based on AAV-mediated gene therapy for retinal dystrophies are ongoing in three labo- ratories (Bainbridge et al., 2008; Maguire et al., 2008; Cideciyan, 2010) our study opens the door to counteracting mitochondrial dysfunction in future clinical studies.”
BackgroundLai, C.-M., Estcourt, M. J., Wikstrom, M., Himbeck, R. P., Barnett, N. L., Brankov, M., Tee, L. B. G., Dunlop, S. A., Degli-Esposti, M. A., & Rakoczy, E. P. (2009) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.08-3253 · Cited by 44
The nonessentiality of essential genes in yeast provides therapeutic insights into a human diseasePreprint
Chen, P., Wang, D., Chen, H., Zhou, Z., & He, X. (2016) · Genome Research · doi:10.1101/gr.205955.116 · Cited by 46
“for these diseases are to restore the lost functions that are believed to be indispensable (Garcia-Blanco et al. 2004; Maguire et al. 2008; Bidou et al. 2012).”
BackgroundCharacterizing the cellular immune response to subretinal AAV gene therapy in the murine retina
Chandler, L. C., McClements, M. E., Yusuf, I. H., Martinez-Fernandez de la Camara, C., MacLaren, R. E., & Xue, K. (2021) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2021.05.011 · Cited by 43
“Many current retinal gene therapy trials adopt a standardized immunosuppression protocol up to 21 days post-treatment, which may ameliorate this immune response in humans.(6,7,40)”
BackgroundBarriers for retinal gene therapy: separating fact from fiction.
Kumar-Singh, R. (2008) · Vision Research · doi:10.1016/j.visres.2008.05.005 · Cited by 43
“However, there is significant evidence that AAV can cause an immune response that is limiting to transgene expression in humans even when similar experiments fail to generate such responses in dogs and mice.”
BackgroundAdvances in salivary gland gene therapy – oral and systemic implications
Baum, B. J., Alevizos, I., Chiorini, J. A., Cotrim, A. P., & Zheng, C. (2015) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2015.1064894 · Cited by 47
Combined Rod and Cone Transduction by Adeno-Associated Virus 2/8
Manfredi, A., Marrocco, E., Puppo, A., Cesi, G., Sommella, A., Della Corte, M., Rossi, S., Giunti, M., Craft, C. M., Bacci, M. L., et al. (2013) · Human Gene Therapy · doi:10.1089/hum.2013.154 · Cited by 43
“…administrations of AAV have been recently demonstrated in patients with Leber congenital amaurosis type 2 (LCA2) (Bainbridge et al., 2008; Cideciyan et al., 2008, 2009a,b, 2013; Hauswirth et al., 2008; Maguire et al., 2008, 2009; Simonelli et al., 2010; Ashtari et al., 2011; Testa et al., 2013).”
BackgroundSelf-citationTargeted gene therapies: tools, applications, optimization
Humbert, O., Davis, L., & Maizels, N. (2012) · Critical Reviews in Biochemistry and Molecular Biology · doi:10.3109/10409238.2012.658112 · Cited by 50
Ciliary Trafficking: CEP290 Guards a Gated Community
Betleja, E., & Cole, D. G. (2010) · Current Biology · doi:10.1016/j.cub.2010.09.058 · Cited by 42
Massively parallel sequencing for early molecular diagnosis in Leber congenital amaurosis
Coppieters, F., Wilde, B. D., Lefever, S., Meester, E. D., Rocker, N. D., Cauwenbergh, C. V., Pattyn, F., Meire, F. M., Leroy, B. P., Hellemans, J., et al. (2012) · Genetics in Medicine · doi:10.1038/gim.2011.51 · Cited by 46
Gene Therapy for MERTK-Associated Retinal Degenerations
LaVail, M. M., Yasumura, D., Matthes, M. T., Yang, H., Hauswirth, W. W., Deng, W.-T., & Vollrath, D. (2016) · Advances in Experimental Medicine and Biology · doi:10.1007/978-3-319-17121-0_65 · Cited by 43
“Three separate Phase I clinical trials for Leber congenital amaurosis type 2 have demonstrated the safety of AAV2 in human patients (Jacobson et al. 2006; Bainbridge et al. 2008; Cideciyan et al. 2008; Maguire et al. 2008).”
BackgroundGenetic manipulation for inherited neurodegenerative diseases: myth or reality?
Yu-Wai-Man, P. (2016) · British Journal of Ophthalmology · doi:10.1136/bjophthalmol-2015-308329 · Cited by 43
Greenwald, S. H., Charette, J. R., Staniszewska, M. M., Shi, L. Y., Brown, S. D. M., Stone, L. V., Liu, Q., Hicks, W. L., Collin, G. B., Bowl, M. R., et al. (2016) · American Journal Of Pathology · doi:10.1016/j.ajpath.2016.03.013 · Cited by 47
Self-citationAAV-CRISPR/Cas9–Mediated Depletion of VEGFR2 Blocks Angiogenesis In Vitro
Wu, W., Duan, Y., Ma, G., Zhou, G., Park-Windhol, C., D'Amore, P. A., & Lei, H. (2017) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.17-21902 · Cited by 42
“692) and to retina for Leber’s congenital amaurosis.(44,45) Thus, we adapted the dual AAV system for delivering CRISPR/Cas9 into HRECs.”
MethodTranslating CRISPR-Cas Therapeutics: Approaches and Challenges
Tay, L. S., Palmer, N. D., Panwala, R., Chew, W. L., & Mali, P. (2020) · The CRISPR Journal · doi:10.1089/crispr.2020.0025 · Cited by 48
Stingl, K. T., Kempf, M., Bartz‐Schmidt, K. U., Dimopoulos, S., Reichel, F. F., Jung, R., Kelbsch, C., Kohl, S., Kortüm, F. C., Nasser, F., et al. (2021) · British Journal of Ophthalmology · doi:10.1136/bjophthalmol-2020-318286 · Cited by 43
PEG–PLA microparticles for encapsulation and delivery of Tat-EGFP to retinal cells
Rafat, M., Cléroux, C. A., Fong, W. G., Baker, A. N., Leonard, B. C., O’Connor, M. D., & Tsilfidis, C. (2010) · Biomaterials · doi:10.1016/j.biomaterials.2010.01.031 · Cited by 47
Success in sight: The eyes have it! Ocular gene therapy trials for LCA look promising
Bainbridge, J. W., & Ali, R. R. (2008) · Gene Therapy · doi:10.1038/gt.2008.117 · Cited by 43
Gene Augmentation for adRP Mutations in RHO
Lewin, A. S., Rossmiller, B., & Mao, H. (2014) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a017400 · Cited by 43
“In three trials of gene therapy for Leber congenital amaurosis type II, AAV serotype 2 has been shown to be safe for human use (Bainbridge et al. 2008; Maguire et al. 2008; Cideciyan et al. 2009).”
BackgroundIn Situ Detection of Adeno-associated Viral Vector Genomes with SABER-FISH
Wang, S. K., Lapan, S. W., Hong, C. M., Krause, T. B., & Cepko, C. L. (2020) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2020.10.003 · Cited by 36
“In recent years, use of AAV vectors in patients has grown tremendously, highlighted by the advent of gene therapy treatments for Leber’s congenital amaurosis and spinal muscular atrophy.(8,9) The translational potential of AAV vectors has now led to more than 200 phase I, II, and III clinical trials (https://clinicalt…”
BackgroundVillate-Beitia, I., Gallego, I., Martínez-Navarrete, G., Zárate, J., López-Méndez, T., Soto-Sánchez, C., Santos-Vizcaíno, E., Puras, G., Fernández, E., & Pedraz, J. L. (2018) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2018.07.035 · Cited by 42
Gene therapy and transplantation in the retinofugal pathway
Harvey, A. R., Hellström, M., & Rodger, J. (2009) · Progress in brain research · doi:10.1016/s0079-6123(09)17510-6 · Cited by 49
“, 2008) and trials for AAV transduction of photoreceptors have also begun (Bainbridge et al., 2008; Maguire et al., 2008).”
BackgroundMicro-/nano-electroporation for active gene delivery
Yang, Z., Chang, L., Chiang, C., & Lee, L. J. (2015) · Current Pharmaceutical Design · doi:10.2174/1381612821666151027152121 · Cited by 44
“Since then, a variety of gene delivery trials have been performed in vivo for the treatment of different diseases such as cancer, amyloidosis, and hypercholesterolemia [6-8].”
BackgroundBoye, S. L., Peterson, J. J., Choudhury, S., Min, S. H., Ruan, Q., McCullough, K. T., Zhang, Z., Olshevskaya, E. V., Peshenko, I. V., Hauswirth, W. W., et al. (2015) · Human Gene Therapy · doi:10.1089/hum.2015.053 · Cited by 42
Yuan, Z., Qiao, C., Hu, P., Li, J., & Xiao, X. (2011) · Human Gene Therapy · doi:10.1089/hum.2010.241 · Cited by 42
“…using AAV vectors to treat genetic diseases such as hemophilia (Margaritis and High, 2010), muscular dystrophy (Wang et al., 2000; Chamberlain, 2002; Mendell et al., 2009, 2010a,b), Leber’s congenital amaurosis (Maguire et al., 2008, 2009), and alpha-1 antitrypsin deficiency (Brantly et al., 2009).”
MethodAllocca, M., Manfredi, A., Iodice, C., Di Vicino, U., & Auricchio, A. (2011) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.10-6269 · Cited by 42
Self-citationChung, D. C., Fogelgren, B., Park, K. M., Heidenberg, J., Zuo, X., Huang, L., Bennett, J., & Lipschutz, J. H. (2011) · Nephron Extra · doi:10.1159/000333071 · Cited by 48
Self-citationEfficacy of Codelivery of Dual AAV2/5 Vectors in the Murine Retina and Hippocampus
Palfi, A., Chadderton, N., McKee, A. G., Blanco Fernandez, A., Humphries, P., Kenna, P. F., & Farrar, G. J. (2012) · Human Gene Therapy · doi:10.1089/hum.2011.142 · Cited by 42
“These trials encompass diverse tissue and organ targets including, for example, the eye and brain (Bainbridge et al., 2008; Hauswirth et al., 2008; Maguire et al., 2008; Marks et al., 2008; Christine et al., 2009; Mandel et al., 2010; MacLachlan et al., 2011).”
Systemic low‐molecular weight drug delivery to pre‐selected neuronal regions
Campbell, M., Humphries, M. M., Kiang, A., Nguyen, A. T. H., Gobbo, O. L., Tam, L. C. S., Suzuki, M., Hanrahan, F., Ozaki, E., Farrar, G. ‐., et al. (2011) · EMBO Molecular Medicine · doi:10.1002/emmm.201100126 · Cited by 42
Personalised genome editing – The future for corneal dystrophies
Moore, T., Christie, K. A., Marshall, J., & Nesbit, M. A. (2018) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2018.01.004 · Cited by 45
The rapidly evolving state of gene therapy
Gruntman, A. M., & Flotte, T. R. (2018) · The FASEB Journal · doi:10.1096/fj.201700982r · Cited by 42
Use of Virtual Reality Simulation to Identify Vision-Related Disability in Patients With Glaucoma
Lam, A. K. N., To, E., Weinreb, R. N., Yu, M., Mak, H. K., Lai, G. W. K., Chiu, V. S. M., Wu, K., Zhang, X. J., Cheng, T. P. H., et al. (2020) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2020.0392 · Cited by 49
Glycosidic enzymes enhance retinal transduction following intravitreal delivery of AAV2.
Cehajic‐Kapetanovic, J., Goff, M. L., Allen, A. E., Lucas, R. J., & Bishop, P. N. (2011) · PubMed Central · Cited by 63
Gene Therapy Targeting Glaucoma: Where Are We?
Liu, X., Rasmussen, C. A., Gabelt, B. T., Brandt, C. R., & Kaufman, P. L. (2009) · Survey of Ophthalmology · doi:10.1016/j.survophthal.2009.04.003 · Cited by 42
“In two separate clinical trials, research teams have reported partially restoring vision using gene therapy to treat advanced cases of LCA.(9,78)”
Choroideremia: Towards a Therapy
Kalatzis, V., Hamel, C., & MacDonald, I. M. (2013) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2013.05.009 · Cited by 45
Targeted approaches for gene therapy and the emergence of engineered meganucleases
Galetto, R., Duchateau, P., & Pâques, F. (2009) · Expert Opinion on Biological Therapy · doi:10.1517/14712590903213669 · Cited by 42
“This tremendous achievement was followed by significant success in other clinical trials addressing different diseases, including another form of SCID [3], epidermolysis bullosa [4] and Leber’s amaurosis [5,6].”
BackgroundAartsen, W. M., van Cleef, K. W. R., Pellissier, L. P., Hoek, R. M., Vos, R. M., Blits, B., Ehlert, E. M. E., Balaggan, K. S., Ali, R. R., Verhaagen, J., et al. (2010) · PLoS ONE · doi:10.1371/journal.pone.0012387 · Cited by 41
Advances in ophthalmic optogenetics: approaches and applications
Prosseda, P. P., Tran, M., Kowal, T., Wang, B., & Sun, Y. (2022) · Biomolecules · doi:10.3390/biom12020269 · Cited by 41
“Clinical trials for gene therapy to treat LCA have demonstrated the safety and efficacy of subretinal delivery of transgenes to the retina via an AAV2 vector [92,93].”
BackgroundGene therapy with regulatory T cells: A beneficial alliance
Biswas, M., Kumar, S. R. P., Terhorst, C., & Herzog, R. W. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00554 · Cited by 41
“Expert Rev Hematol (2010) 3(4):469–83.”
InfluentialNystagmus and saccadic intrusions
Thurtell, M. J., & Leigh, R. J. (2011) · Handbook of clinical neurology · doi:10.1016/b978-0-444-52903-9.00019-4 · Cited by 48
Pseudo-Fovea Formation After Gene Therapy for RPE65-LCA
Cideciyan, A. V., Aguirre, G. K., Jacobson, S. G., Butt, O. H., Schwartz, S., Świder, M., Román, A. J., Sadigh, S., & Hauswirth, W. W. (2014) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.14-15895 · Cited by 44
Early-Onset Foveal Involvement in Retinitis Punctata Albescens With Mutations in RLBP1
Dessalces, E., Bocquet, B., Bourien, J., Zanlonghi, X., Verdet, R., Meunier, I., & Hamel, C. P. (2013) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2013.4476 · Cited by 41
Li, S., Izumi, T., Hu, J., Jin, H. H., Siddiqui, A.-A. A., Jacobson, S. G., Bok, D., & Jin, M. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.552117 · Cited by 41
Twins Eye Study in Tasmania (TEST): Rationale and Methodology to Recruit and Examine Twins
Mackey, D. A., MacKinnon, J. R., Brown, S. A., Kearns, L. S., Ruddle, J. B., Sanfilippo, P. G., Sun, C., Hammond, C. J., Young, T. L., Martin, N. G., et al. (2009) · Twin Research and Human Genetics · doi:10.1375/twin.12.5.441 · Cited by 43
“We used existing microsatellite data to analyze linkage for axial length (AL) using 1790 eyes (Zhu et al., 2008).”
MethodBhere, D., Tamura, K., Wakimoto, H., Choi, S. H., Purow, B. W., Debatisse, J., & Shah, K. (2017) · Neuro-Oncology · doi:10.1093/neuonc/nox138 · Cited by 43
RetractedMicrospheres as intraocular therapeutic tools in chronic diseases of the optic nerve and retina
Bravo‐Osuna, I., Andrés‐Guerrero, V., Arranz-Romera, A., Esteban-Pérez, S., Molina-Martínez, I. T., & Herrero‐Vanrell, R. (2018) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2018.01.007 · Cited by 44
“However, although there is no cure for RP, there has been outstanding advance in underlying genetic and molecular mechanisms to understand the pathology, which has led to restoration of vision in specific cases, such as in patients with a mutation in a gene coding for the retinal pigment epithelium protein RPE65, esse…”
New technologies for developing second generation retinal prostheses
Benfenati, F., & Lanzani, G. (2018) · Lab Animal · doi:10.1038/s41684-018-0003-1 · Cited by 41
The influence of subretinal injection pressure on the microstructure of the monkey retina
Takahashi, K., Morizane, Y., Hisatomi, T., Tachibana, T., Kimura, S., Hosokawa, M. M., Shiode, Y., Hirano, M., Doi, S., Toshima, S., et al. (2018) · PLOS ONE · doi:10.1371/journal.pone.0209996 · Cited by 37
Adeno-Associated Virus-Based Gene Therapy for Lifelong Correction of Genetic Disease
Brommel, C. M., Cooney, A. L., & Sinn, P. L. (2020) · Human Gene Therapy · doi:10.1089/hum.2020.138 · Cited by 47
“Luxturna is an AAV2 vector expressing the retinal pigment epithelium-specific 65 kDa protein (RPE65) that is injected into the retina as a treatment for Leber’s congenital amaurosis.(3) More recently, an AAV9 carrying survival motor neuron 1 (SMN1), termed Zolgensma, was approved for children with spinal muscular atro…”
MethodAdeno-Associated Virus Serotype 2–hCHM Subretinal Delivery to the Macula in Choroideremia
Alemán, T. S., Huckfeldt, R. M., Serrano, L. W., Pearson, D. J., Vergilio, G. K., McCague, S., Marshall, K. A., Ashtari, M., Doan, T. M., Weigel-DiFranco, C., et al. (2022) · Ophthalmology · doi:10.1016/j.ophtha.2022.06.006 · Cited by 42
Self-citation(2011) · PubMed Central · Cited by 41
Chiu, T., Wang, M.-J., & Su, C. (2012) · Journal of Biomedical Science · doi:10.1186/1423-0127-19-45 · Cited by 42
“In 2010, rAAV2mediated transfer of the normal RPE65 gene into the retina of patients with Leber’s congenital amaurosis promoted expression of the transferred gene for at least one year and patients experienced satisfactory therapeutic responses [11].”
BackgroundKautzmann, M.-A. I., Kim, D. S., Felder‐Schmittbuhl, M., & Swaroop, A. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.257246 · Cited by 48
Gene Therapy of ABCA4-Associated Diseases
Auricchio, A., Trapani, I., & Allikmets, R. (2015) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a017301 · Cited by 41
“…in small and large animal models (Stieger et al. 2010) and have paved the way to the first clinical trials using AAV in patients with Leber congenital amaurosis, a severe form of childhood blindness (Bainbridge et al. 2008; Maguire et al. 2008, 2009; Cideciyan et al. 2009; Simonelli et al. 2010).”
BackgroundSelf-citationNonclinical Safety Evaluation of scAAV8-RLBP1 for Treatment of RLBP1 Retinitis Pigmentosa
MacLachlan, T. K., Milton, M. N., Turner, O., Tukov, F., Choi, V. W., Penraat, J., Hanks, S. M., Vrouvlianis, J., Leehy, B., Li, H., et al. (2018) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2017.12.001 · Cited by 40
Metadata
- Authors
- Maguire, A. M., Simonelli, F., Pierce, E. A., Pugh, E. N., Mingozzi, F., Bennicelli, J., Banfi, S., Marshall, K. A., Testa, F., Surace, E. M., Rossi, S., Lyubarsky, A., Arruda, V. R., Konkle, B., Stone, E., Sun, J., Jacobs, J., Dell'Osso, L., Hertle, R., Ma, J.-X., Redmond, T. M., Zhu, X., Hauck, B., Zelenaia, O., Shindler, K. S., Maguire, M. G., Wright, J. F., Volpe, N. J., McDonnell, J. W., Auricchio, A., High, K. A., & Bennett, J.
- Affiliations
- Children's Hospital of Philadelphia (US)
- Telethon Institute Of Genetics And Medicine (IT)
- University of Pennsylvania (US)
- University of Iowa (US)
- Veterans Health Administration (US)
- Children's Hospital of Pittsburgh (US)
- University of Oklahoma (US)
- National Eye Institute (US)
- ORCID
- Maguire, Albert M.
- Simonelli, Francesca
- Pierce, Eric A.
- Pugh, Edward N.
- Mingozzi, Federico
- Banfi, Sandro
- Testa, Francesco
- Surace, Enrico M.
- Rossi, Settimio
- Arruda, Valder R.
- Konkle, Barbara
- Stone, Edwin
- Sun, Junwei
- Hertle, Richard
- Ma, Jian-xing
- Redmond, T. Michael
- Zhu, Xiaosong
- Shindler, Kenneth S.
- Maguire, Maureen G.
- Wright, J. Fraser
- Volpe, Nicholas J.
- Auricchio, Alberto
- High, Katherine A.
- Bennett, Jean
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2008-05-22
- Volume
- 358
- Issue
- 21
- Pages
- 2240-2248
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC2829748
- OpenAlex
- W2137222303
- Cited by
- 2,145
- References
- 27
- Citations by year
- 2026: 38 · 2025: 68 · 2024: 51 · 2023: 66 · 2022: 79 · 2021: 110 · 2020: 96 · 2019: 98 · 2018: 118 · 2017: 144 · 2016: 124 · 2015: 172 · 2014: 152 · 2013: 155 · 2012: 158
- FWCI
- 70.29
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Archivio Istituzionale della Ricerca - Università degli Studi della Campania "Luigi Vanvitelli" (submittedVersion)
- Funders
- Howard Hughes Medical Institute
- National Eye Institute (EY10820, R01EY010820)
- National Center for Research Resources (UL1RR024134)
- Topics
- Health Sciences › Medicine › Ophthalmology › Retinal Development and Disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
- Keywords
- Leber congenital amaurosis, RPE65, gene therapy, adeno-associated virus vectors, retinal pigment epithelium, macular hole, visual acuity, retinal function, adverse events, inherited retinal degeneration
- MeSH terms
- Retinoid Isomerohydrolase, Dependovirus, Adult, Blindness, Carrier Proteins, Eye Proteins, Genetic Vectors, Humans, Injections, Mutation, Promoter Regions, Genetic, Reflex, Pupillary, Retina, Retinal Degeneration, Visual Acuity, Genetic Therapy, Gene Transfer Techniques, DNA, Complementary, cis-trans-Isomerases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.